Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Temozolomide is a chemotherapeutic agent that is used in the treatment of glioblastoma and other malignant gliomas. It acts through DNA alkylation, but treatment is limited by its systemic toxicity and neutralization of DNA alkylation by upregulation of the O-methylguanine-DNA methyltransferase gene. Both of these limiting factors can be addressed by achieving higher concentrations of TMZ in the brain. Our research has led to the discovery of new analogs of temozolomide with improved brain:plasma ratios when dosed in vivo in rats. These compounds are imidazotetrazine analogs, expected to act through the same mechanism as temozolomide. With reduced systemic exposure, these new agents have the potential to improve efficacy and therapeutic index in the treatment of glioblastoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2016.08.064 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring Differentially Expressed Genes and Understanding the Underlying Mechanisms in Glioblastoma.
Biochem Genet
September 2025
Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University Cerrahpasa, Kocamustafapasa, 34098, Istanbul, Turkey.
Glioblastoma is the most aggressive and malignant tumor of the central nervous system. Current treatment options, including surgical excision, radiotherapy, and chemotherapy, have Limited efficacy, with a median survival rate of approximately 15 months. To develop novel therapeutics, it is crucial to understand the underlying molecular mechanisms driving glioblastoma.
View Article and Find Full Text PDFHydrogen sulfide inhibits recruitment of monocyte-derived tumor associated macrophages in glioblastoma by downregulating CXCL12.
Redox Biol
September 2025
Department of Neurosurgery, LSU Health Shreveport, Shreveport, LA, 71103, United States. Electronic address:
Tumor associated macrophages (TAMs) directly contribute to the dismal prognosis of glioblastoma by preventing anti-tumor immunity and promoting tumor invasion and angiogenesis. Inhibiting TAM infiltration is a potential therapeutic strategy in glioblastoma, with several chemokine antagonists in early clinical development. Hydrogen sulfide, a gasotransmitter that regulates microglial accumulation in a wide range of CNS diseases, may be a novel therapeutic target to prevent TAM recruitment in glioblastoma.
View Article and Find Full Text PDFAdvances in neuroscientific mechanisms and therapies for glioblastoma.
iScience
September 2025
Department of Molecular Pathology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, QingDao, Shandong 266300, China.
Gliomas are common primary brain tumors in the central nervous system, characterized by invasiveness, heterogeneity, and drug resistance, posing a threat to patients' lives. Glioblastoma (IDH wild-type) exhibits the highest invasiveness and mortality rate, making it a challenging therapeutic target. This review first outlines the characteristics of gliomas and their impact on the nervous system, then explores the pathological mechanisms and unique behaviors of glioblastoma (IDH wild-type), as well as the influence of the nervous system on its occurrence and progression.
View Article and Find Full Text PDFRadiomics features from the peritumoral region can be associated with the epilepsy status of glioblastoma patients.
Front Oncol
August 2025
Department of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
Purpose: Identifying radiomics features that help predict whether glioblastoma patients are prone to developing epilepsy may contribute to an improvement of preventive treatment and a better understanding of the underlying pathophysiology.
Materials And Methods: In this retrospective study, 3-T MRI data of 451 pretreatment glioblastoma patients (mean age: 61.2 ± 11.
Epithelioid glioblastoma mimicking metastatic brain tumor: A case report and literature review.
Radiol Case Rep
November 2025
Department of Neurosurgery, Hitachi General Hospital, 2-1-1 Jonancho, Hitachi 317-0077, Japan.
Epithelioid glioblastoma (eGBM) is a rare subtype of glioblastoma, generally associated with a poorer prognosis than conventional GBM despite maximum resection and standard chemoradiotherapy. Here, we report a case of a 78-year-old man who presented with left hemiplegia and a well-circumscribed right frontal lobe lesion on imaging, initially suspected to be a metastatic brain tumor. Surgical resection revealed a firm, clearly demarcated mass.
View Article and Find Full Text PDF